Updates are available Correction dated 2025-04-09
Click to view Correction: https://doi.org/10.1007/s11325-025-03321-3
-
Authors
Winter, Yaroslav https://orcid.org/0000-0001-9854-4038
Mayer, Geert
Benes, Heike
Burghaus, Lothar
Floam, Samantha
Parks, Gregory S.
Kallweit, Ulf
-
Funding
Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
- License Information
-
More Information
Article History
Received: 12 September 2024
Revised: 31 January 2025
Accepted: 3 February 2025
First Online: 27 February 2025
Change Date: 3 April 2025
Change Type: Update
Change Details: The original online version of this article was revised: In the originally published version of this article, the article title was incorrectly given as “Patients with obstructive sleep apnea in Germany.” This has been corrected to read “SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.”
Change Date: 9 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11325-025-03321-3
Declarations
:
: This study was conducted in accordance with applicable national and local requirements for good research study practices. Required country-specific documentation was reviewed and approved, per local regulations, before any patient chart data were included in the study. Because all patient chart data were de-identified and anonymous to the sponsor, informed consent was not required from patients, based on international regulations, including the General Data Protection Regulation.
: Y Winter has received honoraria for educational presentations and consultations from Angelini Pharma, Axsome Therapeutics, Avextra Pharma, Bayer AG, BIAL, Bioprojet, Bristol Myers Squibb, Eisai, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, LivaNova, Novartis, and UCB Pharma. G Mayer has received honoraria for consultation and educational presentations by Idorsia, Pharmanovia, and Takeda. H Benes and L Burghaus have nothing to disclose. S Floam is an employee of Axsome Therapeutics. G Parks is a former employee of Axsome Therapeutics. U Kallweit is on the advisory board at Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, and Takeda Pharma. He is also a consultant to AOP Orphan Pharmaceuticals, Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, and Takeda Pharma and has accepted institutional grants/research support from Bioprojet Pharma, Harmony Biosciences, and Jazz Pharmaceuticals.
